Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

PURPOSE: Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Maurer, Matthew J., Ghesquières, Hervé, Link, Brian K., Jais, Jean-Philippe, Habermann, Thomas M., Thompson, Carrie A., Haioun, Corinne, Allmer, Cristine, Johnston, Patrick B., Delarue, Richard, Micallef, Ivana N., Peyrade, Frederic, Inwards, David J., Ketterer, Nicolas, Farooq, Umar, Fitoussi, Olivier, Macon, William R., Molina, Thierry J., Syrbu, Sergei, Feldman, Andrew L., Slager, Susan L., Weiner, George J., Ansell, Stephen M., Cerhan, James R., Salles, Gilles A., Witzig, Thomas E., Tilly, Hervé, Nowakowski, Grzegorz S.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2018
Onderwerpen:
ORIGINAL REPORTS
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5978469/
https://ncbi.nlm.nih.gov/pubmed/29672223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.5198
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items